Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

16 Apr 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31038154
DOI: 10.1093/annonc/mdz119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsPMID 31038154Read ↗

Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testingSemantic proximity Read ↗

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French studySemantic proximity Read ↗

Improving public cancer care by implementing precision medicine in Norway - IMPRESS-NorwaySemantic proximity Read ↗

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act CoverageSemantic proximity Read ↗

Value-based genomicsSemantic proximity Read ↗

The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.Semantic proximity Read ↗

Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative.Semantic proximity Read ↗

The European Union and personalised cancer medicine.Semantic proximity Read ↗

Personalised cancer medicine.Semantic proximity Read ↗

Fear of Cancer Recurrence in an Era of Personalized Medicine.Semantic proximity Read ↗

Lung cancer biomarker testing: perspective from EuropeSemantic proximity Read ↗

The regulatory landscape for actively personalized cancer immunotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.